Team Startupcity

• Ayurvedic healthcare brand Kapiva raised $60M in a funding round led by 360 ONE Asset and Vertex Growth, with existing investors Vertex Ventures SEA and 3one4 Capital also participating.
• Funds will be used for R&D, expanding manufacturing, and growing offline and international presence, with Kapiva aiming to hit 1 lakh offline stores and prepare for an IPO in 2-3 years.
• Kapiva has seen 80% YoY growth, ARR over Rs 550 crore, and growing contributions from UAE, US, UK subsidiaries and speedy commerce apps, reflecting rising demand for ayurvedic and health supplements post-Covid-19.

Ayurvedic healthcare brand Kapiva raised more than $60 million funding headed by 360 ONE Asset and Vertex Growth and existing shareholders Vertex Ventures Southeast Asia and 3one4 Capital also joined the round.

While a portion of the total amount, $28 million, was primary capital and $32 million secondary transactions, through which early backer Fireside Ventures will be exiting, Kapiva's founder Ameve Sharma said. The company intends to utilize the funds for research and development of new products, enhancing its manufacturing capacity and increasing presence in new geographies.

"This was our pre-IPO fundraise and now we will be going towards our IPO years", Sharma informed. The firm is going to have its IPO within the next 2-3 years.

The major categories of Kapiva are diabetes care products, energy, sports, nutrition, liver and heart. These sell through its own direct-to-consumer website, marketplace and offline channels. The brand has presence in more than 40,000 offline stores as of now, its fastest growing channel, and looks to reach 1 lakh offline stores in a year.

“We are trying to reimagine Ayurveda for its current role within the larger healthcare system not only in India but also globally”, said Sharma. Currently, Kapiva has subsidiaries in UAE, US and UK that contribute 5-10% to its overall revenue annually.

Also Read: CityMall Raises $47M to Power E-commerce Growth in Bharat

The brand is also experiencing fast growth on speedy commerce apps which is contributing 10% of its revenue. In the last three years, Kapiva has experienced an 80% year-on-year growth with an annual revenue run rate (ARR) of more than Rs 550 crore.

The market for supplements has experienced rising consumption post-Covid-19 and ayurvedic products, in particular, are experiencing rising customer demand with the central government giving a boost to such products.

Increased customer demand for supplements and healthcare products has made venture capitalists invest in the industry. The industry raised over $500 million from 2020 to May 2025, according to data firm Venture Intelligence.

Gut health firm The Good Bug raised around $12 million in a round headed by Susquehanna Asia Venture Capital. ET had in May written about the booming India health supplement space, driven by growing health consciousness post Covid-19 and social media promotions.